<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39051242</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2036-7430</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Infectious disease reports</Title><ISOAbbreviation>Infect Dis Rep</ISOAbbreviation></Journal><ArticleTitle>Persistent Vascular Complications in Long COVID: The Role of ACE2 Deactivation, Microclots, and Uniform Fibrosis.</ArticleTitle><Pagination><StartPage>561</StartPage><EndPage>571</EndPage><MedlinePgn>561-571</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/idr16040042</ELocationID><Abstract><AbstractText>Angiotensin-converting enzyme 2 (ACE2), a key regulator in vasoregulation and the renin-angiotensin system, is hypothesized to be downregulated in patients with COVID-19, leading to a cascade of cardiovascular complications. This deactivation potentially results in increased blood pressure and vessel injury, contributing to the formation and persistence of microclots in the circulation. Herein, we propose a hypothesis regarding the prolonged vascular complications observed in long COVID, focusing on the role of ACE2 deactivation and/or shedding, the persistence of microclots, and the unique pattern of fibrosis induced by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Furthermore, we propose that the distinctive, uniform fibrosis associated with COVID-19, which is challenging to detect through conventional X-ray imaging, exacerbates vascular injury and impairs oxygenation. The persistence of these microclots and the unique fibrosis pattern are suggested as key factors in the extended duration of vascular complications post-COVID-19 infection, regardless of the initial disease severity. Moreover, plasma ACE2 activity has the potential to serve as prognostic or diagnostic biomarkers for monitoring disease severity and managing long COVID symptoms. Elucidating the role of ACE2 deactivation and the consequent events is vital for understanding the long-term effects of COVID-19. The experimental verification of this hypothesis through in vitro studies, clinical longitudinal studies, and advanced imaging techniques could yield significant insights into the pathophysiological mechanisms underlying long COVID, thereby improving the management of patients, particularly those with cardiovascular complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sideratou</LastName><ForeName>Christina-Michailia</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, School of Life and Health Sciences, University of Nicosia, 2417 Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papaneophytou</LastName><ForeName>Christos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4045-8839</Identifier><AffiliationInfo><Affiliation>Department of Life Sciences, School of Life and Health Sciences, University of Nicosia, 2417 Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Infect Dis Rep</MedlineTA><NlmUniqueID>101537203</NlmUniqueID><ISSNLinking>2036-7430</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2</Keyword><Keyword MajorTopicYN="N">RAS</Keyword><Keyword MajorTopicYN="N">fibrosis</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">microclots</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome-coronavirus-2</Keyword><Keyword MajorTopicYN="N">vasoregulation</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39051242</ArticleId><ArticleId IdType="pmc">PMC11270324</ArticleId><ArticleId IdType="doi">10.3390/idr16040042</ArticleId><ArticleId IdType="pii">idr16040042</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stawicki S.P., Jeanmonod R., Miller A.C., Paladino L., Gaieski D.F., Yaffee A.Q., De Wulf A., Grover J., Papadimos T.J., Bloem C., et al. The 2019&#x2013;2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper. J. Glob. Infect. Dis. 2020;12:47&#x2013;93. doi: 10.4103/jgid.jgid_86_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jgid.jgid_86_20</ArticleId><ArticleId IdType="pmc">PMC7384689</ArticleId><ArticleId IdType="pubmed">32773996</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan V.J., Bambra C. COVID-19 mortality and deprivation: Pandemic, syndemic, and endemic health inequalities. Lancet Public Health. 2022;7:e966&#x2013;e975. doi: 10.1016/S2468-2667(22)00223-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(22)00223-7</ArticleId><ArticleId IdType="pmc">PMC9629845</ArticleId><ArticleId IdType="pubmed">36334610</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;elik I., &#xd6;zt&#xfc;rk R. From asymptomatic to critical illness: Decoding various clinical stages of COVID-19. Turk. J. Med. Sci. 2021;51:3284&#x2013;3300. doi: 10.3906/sag-2107-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.3906/sag-2107-13</ArticleId><ArticleId IdType="pmc">PMC8771010</ArticleId><ArticleId IdType="pubmed">34445855</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M., Volzke J., Subin B., Schmidt C.J., Geerdes-Fenge H., Reisinger E.C., M&#xfc;ller-Hilke B. Distinguishing incubation and acute disease stages of mild-to-moderate COVID-19. Viruses. 2022;14:203. doi: 10.3390/v14020203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14020203</ArticleId><ArticleId IdType="pmc">PMC8875077</ArticleId><ArticleId IdType="pubmed">35215797</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Andrade B., Siqueira S., de Assis Soares W.R., de Souza Rangel F., Santos N.O., dos Santos Freitas A., Ribeiro da Silveira P., Tiwari S., Alzahrani K.J., G&#xf3;es-Neto A., et al. Long-COVID and post-COVID health complications: An up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13:700. doi: 10.3390/v13040700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040700</ArticleId><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sideratou C.-M., Papaneophytou C. Persisting shadows: Unraveling the impact of long COVID-19 on respiratory, cardiovascular, and nevous systems. Infect. Dis. Rep. 2023;15:806&#x2013;830. doi: 10.3390/idr15060072.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/idr15060072</ArticleId><ArticleId IdType="pmc">PMC10742861</ArticleId><ArticleId IdType="pubmed">38131885</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M. ACE2 and COVID-19 susceptibility and severity. Aging Dis. 2022;13:360&#x2013;372. doi: 10.14336/AD.2021.0805.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2021.0805</ArticleId><ArticleId IdType="pmc">PMC8947832</ArticleId><ArticleId IdType="pubmed">35371596</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya Y., Alameer A., Calpin G., Alkhattab M., Sultan S. A comprehensive review of vascular complications in COVID-19. J. Thromb. Thrombolysis. 2022;53:586&#x2013;593. doi: 10.1007/s11239-021-02593-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02593-2</ArticleId><ArticleId IdType="pmc">PMC8558544</ArticleId><ArticleId IdType="pubmed">34724155</ArticleId></ArticleIdList></Reference><Reference><Citation>Harenberg J., Favaloro E. COVID-19: Progression of disease and intravascular coagulation&#x2014;Present status and future perspectives. Clin. Chem. Lab Med. 2020;58:1029&#x2013;1036. doi: 10.1515/cclm-2020-0502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0502</ArticleId><ArticleId IdType="pubmed">32406381</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033&#x2013;2040. doi: 10.1182/blood.2020006000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020006000</ArticleId><ArticleId IdType="pmc">PMC7273827</ArticleId><ArticleId IdType="pubmed">32339221</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J., Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: Origins and therapeutic implications. Biochem. J. 2022;479:537&#x2013;559. doi: 10.1042/BCJ20220016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220016</ArticleId><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., Venter C., Vlok M., Ngoepe M., Laubscher G.J., Lourens P.J., Steenkamp J., Kell D.B., Pretorius E. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. Biosci. Rep. 2021;41:BSR2021061. doi: 10.1042/BSR20210611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20210611</ArticleId><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins-Gon&#xe7;alves R., Campos M.M., Palhinha L., Azevedo-Quintanilha I.G., Mendes M.A., Temerozo J.R., Toledo-Mendes J., Rosado-de-Castro P.H., Bozza F.A., Rodrigues R.S., et al. Persisting platelet activation and hyperactivity in COVID-19 survivors. Circ. Res. 2022;131:944&#x2013;947. doi: 10.1161/CIRCRESAHA.122.321659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.122.321659</ArticleId><ArticleId IdType="pmc">PMC9645447</ArticleId><ArticleId IdType="pubmed">36268747</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Fogarty H., Dyer A., Martin-Loeches I., Bannan C., Nadarajan P., Bergin C., O&#x2019;Farrelly C., Conlon N., Bourke N.M., et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J. Thromb. Haemost. 2021;19:1064&#x2013;1070. doi: 10.1111/jth.15267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15267</ArticleId><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasini E., Corsetti G., Romano C., Scarabelli T.M., Chen-Scarabelli C., Saravolatz L., Dioguardi F.S. Serum metabolic profile in patients with long-COVID (PASC) syndrome: Clinical implications. Front. Med. 2021;8:714426. doi: 10.3389/fmed.2021.714426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.714426</ArticleId><ArticleId IdType="pmc">PMC8339407</ArticleId><ArticleId IdType="pubmed">34368201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan B.E., Wong S.W., Sum C.L.L., Lim G.H., Leung B.P., Tan C.W., Ramanathan K., Dalan R., Cheung C., Lim X.R., et al. Hypercoagulability, endotheliopathy, and inflammation approximating 1&#x2009;year after recovery: Assessing the long-term outcomes in COVID-19 patients. Am. J. Hematol. 2022;97:915&#x2013;923. doi: 10.1002/ajh.26575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26575</ArticleId><ArticleId IdType="pmc">PMC9073976</ArticleId><ArticleId IdType="pubmed">35477923</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt F.A., Havervall S., Adelmeijer J., Lundstr&#xf6;m A., Magnusson M., Mackman N., Thalin C., Lisman T. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv. 2021;5:756&#x2013;759. doi: 10.1182/bloodadvances.2020003968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003968</ArticleId><ArticleId IdType="pmc">PMC7857699</ArticleId><ArticleId IdType="pubmed">33560386</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannis D., Allen S.L., Tsang J., Flint S., Pinhasov T., Williams S., Tan G., Thakur R., Leung C., Snyder M., et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: The CORE-19 registry. Blood. 2021;137:2838&#x2013;2847. doi: 10.1182/blood.2020010529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020010529</ArticleId><ArticleId IdType="pmc">PMC8032474</ArticleId><ArticleId IdType="pubmed">33824972</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S., Barnett J., Brill S.E., Brown J.S., Denneny E.K., Hare S.S., Heightman M., Hillman T.E., Jacob J., Jarvis H.C., et al. &#x2018;Long-COVID&#x2019;: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396&#x2013;398. doi: 10.1136/thoraxjnl-2020-215818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelen M.M., Vandenbriele C., Balthazar T., Claeys E., Gunst J., Guler I., Jacquemin M., Janssens S., Lorent N., Liesenborghs L., et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin. Thromb. Hemost. 2021;47:362&#x2013;371. doi: 10.1055/s-0041-1727284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1727284</ArticleId><ArticleId IdType="pubmed">33893631</ArticleId></ArticleIdList></Reference><Reference><Citation>Korompoki E., Gavriatopoulou M., Fotiou D., Ntanasis-Stathopoulos I., Dimopoulos M.A., Terpos E. Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. Am. J. Hematol. 2022;97:119&#x2013;128. doi: 10.1002/ajh.26384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26384</ArticleId><ArticleId IdType="pmc">PMC8646944</ArticleId><ArticleId IdType="pubmed">34687462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., Banerjee A. Post-COVID syndrome in individuals admitted to hospital with COVID-19: Retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I., Fonseca-Rodr&#xed;guez O., Farrington P., Jerndal H., Lundevaller E.H., Sund M., Lindmark K., Fors Connolly A.M. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: Nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377:e069590. doi: 10.1136/bmj-2021-069590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069590</ArticleId><ArticleId IdType="pmc">PMC8984137</ArticleId><ArticleId IdType="pubmed">35387772</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam A., Bashir M.S., Joyce K., Rashid H., Laher I., Elshazly S. An update on COVID-19 vaccine induced thrombotic thrombocytopenia syndrome and some management recommendations. Molecules. 2021;26:5004. doi: 10.3390/molecules26165004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26165004</ArticleId><ArticleId IdType="pmc">PMC8400504</ArticleId><ArticleId IdType="pubmed">34443589</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., Langer F., Makris M., Pai M., Pavord S., Tran H., Warkentin T.E. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. J. Thromb. Haemost. 2022;20:149&#x2013;156. doi: 10.1111/jth.15572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15572</ArticleId><ArticleId IdType="pmc">PMC8646430</ArticleId><ArticleId IdType="pubmed">34693641</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani A., Ojha V. Thromboembolism after COVID-19 vaccination: A systematic review of such events in 286 patients. Ann. Vasc. Surg. 2022;84:12&#x2013;20.e1. doi: 10.1016/j.avsg.2022.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.avsg.2022.05.001</ArticleId><ArticleId IdType="pmc">PMC9093198</ArticleId><ArticleId IdType="pubmed">35568325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirico F., Teixeira da Silva J.A., Tsigaris P., Sharun K. Safety &amp; effectiveness of COVID-19 vaccines: A narrative review. Indian J. Med. Res. 2022;155:91&#x2013;104. doi: 10.4103/ijmr.IJMR_474_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmr.IJMR_474_21</ArticleId><ArticleId IdType="pmc">PMC9552389</ArticleId><ArticleId IdType="pubmed">35859436</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirbhate E., Pandey J., Patel V.K., Kamal M., Jawaid T., Gorain B., Kesharwani P., Rajak H. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: A potential approach for therapeutic intervention. Pharmacol. Rep. 2021;73:1539&#x2013;1550. doi: 10.1007/s43440-021-00303-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00303-6</ArticleId><ArticleId IdType="pmc">PMC8236094</ArticleId><ArticleId IdType="pubmed">34176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner A.J., Hiscox J.A., Hooper N.M. ACE2: From vasopeptidase to SARS virus receptor. Trends Pharmacol. Sci. 2004;25:291&#x2013;294. doi: 10.1016/j.tips.2004.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2004.04.001</ArticleId><ArticleId IdType="pmc">PMC7119032</ArticleId><ArticleId IdType="pubmed">15165741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Villalobos R.A., Shen X.Z., Bernstein E.A., Janjulia T., Taylor B., Giani J.F., Blackwell W.L., Shah K.H., Shi P.D., Fuchs S., et al. Rediscovering ACE: Novel insights into the many roles of the angiotensin-converting enzyme. J. Mol. Med. 2013;91:1143&#x2013;1154. doi: 10.1007/s00109-013-1051-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-013-1051-z</ArticleId><ArticleId IdType="pmc">PMC3779503</ArticleId><ArticleId IdType="pubmed">23686164</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S., Rauf A., Khan H., Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed. Pharmacother. 2017;94:317&#x2013;325. doi: 10.1016/j.biopha.2017.07.091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.07.091</ArticleId><ArticleId IdType="pubmed">28772209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I., Cooper M.E., Haagmans B.L., Hooper N.M., Korstanje R., Osterhaus A.D., Timens W., Turner A.J., Navis G., van Goor H. The emerging role of ACE2 in physiology and disease. J. Pathol. 2007;212:1&#x2013;11. doi: 10.1002/path.2162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2162</ArticleId><ArticleId IdType="pmc">PMC7167724</ArticleId><ArticleId IdType="pubmed">17464936</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira C., Nery L., Martins L., Jabour L., Dias R., Sim&#xf5;es E.S.A.C. Downregulation of membrane-bound angiotensin converting enzyme 2 (ACE2) receptor has a pivotal role in COVID-19 immunopathology. Curr. Drug. Targets. 2021;22:254&#x2013;281. doi: 10.2174/18735592MTEwFNzYF3.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/18735592MTEwFNzYF3</ArticleId><ArticleId IdType="pubmed">33081670</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H., Yue X., Lazartigues E. ACE2 mouse models: A toolbox for cardiovascular and pulmonary research. Nat. Commun. 2020;11:5165. doi: 10.1038/s41467-020-18880-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18880-0</ArticleId><ArticleId IdType="pmc">PMC7560817</ArticleId><ArticleId IdType="pubmed">33057007</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Leong-Poi H., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112&#x2013;116. doi: 10.1038/nature03712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03712</ArticleId><ArticleId IdType="pmc">PMC7094998</ArticleId><ArticleId IdType="pubmed">16001071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B., Huan Y., Yang P., Zhang Y., Deng W., et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005;11:875&#x2013;879. doi: 10.1038/nm1267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1267</ArticleId><ArticleId IdType="pmc">PMC7095783</ArticleId><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020;130:2620&#x2013;2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., P&#xe9;r&#xe9; H., Charbit B., Bondet V., Chenevier-Gobeaux C., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718&#x2013;724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Pei S., Chen B., Song Y., Zhang T., Yang W., Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) Science. 2020;368:489&#x2013;493. doi: 10.1126/science.abb3221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3221</ArticleId><ArticleId IdType="pmc">PMC7164387</ArticleId><ArticleId IdType="pubmed">32179701</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X.H., Li T.Y., He Z.C., Ping Y.F., Liu H.W., Yu S.C., Mou H.M., Wang L.H., Zhang H.R., Fu W.J., et al. A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020;49:411&#x2013;417. doi: 10.3760/cma.j.cn112151-20200312-00193.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112151-20200312-00193</ArticleId><ArticleId IdType="pubmed">32172546</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Li S., Liu J., Liang B., Wang X., Wang H., Li W., Tong Q., Yi J., Zhao L., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102763</ArticleId><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D., O&#x2019;Donnell J.S., Sharif K., Emery P., Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2:e437&#x2013;e445. doi: 10.1016/S2665-9913(20)30121-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30121-1</ArticleId><ArticleId IdType="pmc">PMC7252093</ArticleId><ArticleId IdType="pubmed">32835247</ArticleId></ArticleIdList></Reference><Reference><Citation>Samavati L., Uhal B.D. ACE2, much more than just a receptor for SARS-CoV-2. Front. Cell. Infect. Microbiol. 2020;10:317. doi: 10.3389/fcimb.2020.00317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00317</ArticleId><ArticleId IdType="pmc">PMC7294848</ArticleId><ArticleId IdType="pubmed">32582574</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdecchia P., Cavallini C., Spanevello A., Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur. J. Intern. Med. 2020;76:14&#x2013;20. doi: 10.1016/j.ejim.2020.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2020.04.037</ArticleId><ArticleId IdType="pmc">PMC7167588</ArticleId><ArticleId IdType="pubmed">32336612</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiga M., Wang D.W., Han Y., Lewis D.B., Wu J.C. COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 2020;17:543&#x2013;558. doi: 10.1038/s41569-020-0413-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0413-9</ArticleId><ArticleId IdType="pmc">PMC7370876</ArticleId><ArticleId IdType="pubmed">32690910</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel V.B., Zhong J.C., Grant M.B., Oudit G.Y. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ. Res. 2016;118:1313&#x2013;1326. doi: 10.1161/CIRCRESAHA.116.307708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.307708</ArticleId><ArticleId IdType="pmc">PMC4939482</ArticleId><ArticleId IdType="pubmed">27081112</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyerstedt S., Casaro E.B., Rangel &#xc9;.B. COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40:905&#x2013;919. doi: 10.1007/s10096-020-04138-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-04138-6</ArticleId><ArticleId IdType="pmc">PMC7778857</ArticleId><ArticleId IdType="pubmed">33389262</ArticleId></ArticleIdList></Reference><Reference><Citation>Banu N., Panikar S.S., Leal L.R., Leal A.R. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. Life Sci. 2020;256:117905. doi: 10.1016/j.lfs.2020.117905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117905</ArticleId><ArticleId IdType="pmc">PMC7832382</ArticleId><ArticleId IdType="pubmed">32504757</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh J.D., Hoofnagle M.H., Bamezai S., Oxendine M., Lim L., Hall J.D., Yang J., Schultz S., Engel J.D., Kume T., et al. Hemodynamic regulation of perivalvular endothelial gene expression prevents deep venous thrombosis. J. Clin. Investig. 2019;129:5489&#x2013;5500. doi: 10.1172/JCI124791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124791</ArticleId><ArticleId IdType="pmc">PMC6877343</ArticleId><ArticleId IdType="pubmed">31710307</ArticleId></ArticleIdList></Reference><Reference><Citation>Colling M.E., Tourdot B.E., Kanthi Y. Inflammation, infection and venous Thromboembolism. Circ. Res. 2021;128:2017&#x2013;2036. doi: 10.1161/CIRCRESAHA.121.318225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318225</ArticleId><ArticleId IdType="pmc">PMC8202069</ArticleId><ArticleId IdType="pubmed">34110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaumenhaft R., Enjyoji K., Schmaier A.A. Vasculopathy in COVID-19. Blood. 2022;140:222&#x2013;235. doi: 10.1182/blood.2021012250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012250</ArticleId><ArticleId IdType="pmc">PMC8736280</ArticleId><ArticleId IdType="pubmed">34986238</ArticleId></ArticleIdList></Reference><Reference><Citation>Frediansyah A., Nainu F., Dhama K., Mudatsir M., Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin. Epidemiol. Glob. Health. 2021;9:123&#x2013;127. doi: 10.1016/j.cegh.2020.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cegh.2020.07.011</ArticleId><ArticleId IdType="pmc">PMC7410793</ArticleId><ArticleId IdType="pubmed">32838064</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Cheng K., Sch&#xe4;ffer A.A., Aldape K., Schiff E., Ruppin E. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression. Mol. Syst. Biol. 2020;16:e9628. doi: 10.15252/msb.20209628.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.20209628</ArticleId><ArticleId IdType="pmc">PMC7390914</ArticleId><ArticleId IdType="pubmed">32729248</ArticleId></ArticleIdList></Reference><Reference><Citation>Reindl-Schwaighofer R., H&#xf6;dlmoser S., Eskandary F., Poglitsch M., Bonderman D., Strassl R., Aberle J.H., Oberbauer R., Zoufaly A., Hecking M. ACE2 elevation in severe COVID-19. Am. J. Respir. Crit. Care Med. 2021;203:1191&#x2013;1196. doi: 10.1164/rccm.202101-0142LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202101-0142LE</ArticleId><ArticleId IdType="pmc">PMC8314901</ArticleId><ArticleId IdType="pubmed">33600742</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaud V., Deodhar M., Arwood M., Al Rihani S.B., Dow P., Turgeon J. ACE2 as a therapeutic target for COVID-19; Its role in infectious processes and regulation by modulators of the RAAS system. J. Clin. Med. 2020;9:2096. doi: 10.3390/jcm9072096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9072096</ArticleId><ArticleId IdType="pmc">PMC7408699</ArticleId><ArticleId IdType="pubmed">32635289</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H.T., Rhind S.G., Beckett A. Convalescent plasma for the prevention and treatment of COVID-19: A systematic review and quantitative analysis. JMIR Public Health Surveill. 2021;7:e25500. doi: 10.2196/25500.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/25500</ArticleId><ArticleId IdType="pmc">PMC8245055</ArticleId><ArticleId IdType="pubmed">33825689</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevchuk O., Pak A., Palii S., Ivankiv Y., Kozak K., Korda M., Vari S.G. Blood ACE2 protein level correlates with COVID-19 severity. Int. J. Mol. Sci. 2023;24:13957. doi: 10.3390/ijms241813957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241813957</ArticleId><ArticleId IdType="pmc">PMC10530872</ArticleId><ArticleId IdType="pubmed">37762258</ArticleId></ArticleIdList></Reference><Reference><Citation>Su H., Yang M., Wan C., Yi L.X., Tang F., Zhu H.Y., Yi F., Yang H.C., Fogo A.B., Nie X., et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98:219&#x2013;227. doi: 10.1016/j.kint.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7194105</ArticleId><ArticleId IdType="pubmed">32327202</ArticleId></ArticleIdList></Reference><Reference><Citation>Peron J.P.S., Nakaya H. Susceptibility of the elderly to SARS-CoV-2 infection: ACE-2 overexpression, shedding, and antibody-dependent enhancement (ADE) Clinics. 2020;75:e1912. doi: 10.6061/clinics/2020/e1912.</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2020/e1912</ArticleId><ArticleId IdType="pmc">PMC7213670</ArticleId><ArticleId IdType="pubmed">32428113</ArticleId></ArticleIdList></Reference><Reference><Citation>Epelman S., Tang W.H., Chen S.Y., Van Lente F., Francis G.S., Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J. Am. Coll. Cardiol. 2008;52:750&#x2013;754. doi: 10.1016/j.jacc.2008.02.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2008.02.088</ArticleId><ArticleId IdType="pmc">PMC2856943</ArticleId><ArticleId IdType="pubmed">18718423</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S.K., Juno J.A., Lee W.S., Wragg K.M., Hogarth P.M., Kent S.J., Burrell L.M. Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: Implications for COVID-19 pathogenesis and consequences. Eur. Respir. J. 2021;57:2003730. doi: 10.1183/13993003.03730-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03730-2020</ArticleId><ArticleId IdType="pmc">PMC7830336</ArticleId><ArticleId IdType="pubmed">33479113</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H.Y., Patel S.K., Huang P., Tacey M., Choy K.W., Wang J., Donnan G., Nandurkar H.H., Ho P., Burrell L.M. Plasma angiotensin converting enzyme 2 (ACE2) activity in healthy controls and patients with cardiovascular risk factors and/or disease. J. Pers. Med. 2022;12:1495. doi: 10.3390/jpm12091495.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12091495</ArticleId><ArticleId IdType="pmc">PMC9501250</ArticleId><ArticleId IdType="pubmed">36143280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrabadi M.E., Hemmati R., Tashakor A., Homaei A., Yousefzadeh M., Hemati K., Hosseinkhani S. Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity. Biomed. Pharmacother. 2021;137:111363. doi: 10.1016/j.biopha.2021.111363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111363</ArticleId><ArticleId IdType="pmc">PMC7862910</ArticleId><ArticleId IdType="pubmed">33582450</ArticleId></ArticleIdList></Reference><Reference><Citation>South A.M., Tomlinson L., Edmonston D., Hiremath S., Sparks M.A. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat. Rev. Nephrol. 2020;16:305&#x2013;307. doi: 10.1038/s41581-020-0279-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-020-0279-4</ArticleId><ArticleId IdType="pmc">PMC7118703</ArticleId><ArticleId IdType="pubmed">32246101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciceri F., Beretta L., Scandroglio A.M., Colombo S., Landoni G., Ruggeri A., Peccatori J., D&#x2019;Angelo A., De Cobelli F., Rovere-Querini P., et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): An atypical acute respiratory distress syndrome working hypothesis. Crit. Care Resusc. 2020;22:95&#x2013;97. doi: 10.51893/2020.2.pov2.</Citation><ArticleIdList><ArticleId IdType="doi">10.51893/2020.2.pov2</ArticleId><ArticleId IdType="pmc">PMC10692450</ArticleId><ArticleId IdType="pubmed">32294809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hama Amin B.J., Kakamad F.H., Ahmed G.S., Ahmed S.F., Abdulla B.A., Mohammed S.H., Mikael T.M., Salih R.Q., Ali R.K., Salh A.M., et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Ann. Med. Surg. 2022;77:103590. doi: 10.1016/j.amsu.2022.103590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.103590</ArticleId><ArticleId IdType="pmc">PMC8983072</ArticleId><ArticleId IdType="pubmed">35411216</ArticleId></ArticleIdList></Reference><Reference><Citation>Saifi M.A., Bansod S., Godugu C. COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives. Drug Discov. Today. 2022;27:103345. doi: 10.1016/j.drudis.2022.103345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2022.103345</ArticleId><ArticleId IdType="pmc">PMC9444298</ArticleId><ArticleId IdType="pubmed">36075378</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong-Quy S., Vo-Pham-Minh T., Tran-Xuan Q., Huynh-Anh T., Vo-Van T., Vu-Tran-Thien Q., Nguyen-Nhu V. Post-COVID-19 pulmonary fibrosis: Facts-challenges and futures: A narrative review. Pulm. Ther. 2023;9:295&#x2013;307. doi: 10.1007/s41030-023-00226-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41030-023-00226-y</ArticleId><ArticleId IdType="pmc">PMC10199290</ArticleId><ArticleId IdType="pubmed">37209374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryce C., Grimes Z., Pujadas E., Ahuja S., Beasley M.B., Albrecht R., Hernandez T., Stock A., Zhao Z., AlRasheed M.R., et al. Pathophysiology of SARS-CoV-2: The mount Sinai COVID-19 autopsy experience. Mod. Pathol. 2021;34:1456&#x2013;1467. doi: 10.1038/s41379-021-00793-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-021-00793-y</ArticleId><ArticleId IdType="pmc">PMC8015313</ArticleId><ArticleId IdType="pubmed">33795830</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>